Search Results

• • 7 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience

  Authors:Francesca Martella, Carlotta Bacci, Clara Giordano, Francesco Montagnani, Elena Gelain, Loredana Rabatti, et al.From:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20153,826 words Report 1690LAuthor(s): Francesca Martella [*] aff1 , Carlotta Bacci aff1 , Clara Giordano aff1 , Francesco Montagnani aff1 , Elena Gelain aff2 , Loredana Rabatti aff3 , Luisa Fioretto aff1 KEYWORDS eribulin; metastatic breast...

• Retinal metastasis regression with eribulin in a heavily pretreated breast cancer patient

  Authors:Marta Gubbiotti, Barbara Pistilli, Marianna Tudini, Giovanni Benedetti, Eva Galizia, Marco Rusiello, et al.From:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20153,396 words Clinical report 1650LAuthor(s): Marta Gubbiotti aff1 , Barbara Pistilli [*] aff2 , Marianna Tudini aff3 , Giovanni Benedetti aff2 , Eva Galizia aff4 , Marco Rusiello aff2 , Luciano Latini aff2 KEYWORDS brain metastases; breast cancer;...

• Long response to eribulin in breast cancer: a case report

  Authors:Karen Borgonovo, Fausto Petrelli, Mary Cabiddu, Mara Ghilardi, Andrea Coinu, Silvia Seghezzi, et al.From:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20153,089 words Clinical report 1510LAuthor(s): Karen Borgonovo [*] aff1 , Fausto Petrelli aff1 , Mary Cabiddu aff1 , Mara Ghilardi aff1 , Andrea Coinu aff1 , Silvia Seghezzi aff2 , Sandro Barni aff1 KEYWORDS breast cancer; chemotherapy; eribulin...

• Eribulin in 'field practice': an overview of the Italian experience

  Author:Sandro BarniFrom:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 2015989 words Report 1760LAuthor(s): Sandro Barni [*] aff1 KEYWORDS breast cancer; case study; erbulin mesylate Breast cancer remains the most common oncological disease in women. Although the diagnostic and therapeutic advantages...

• Benefit of eribulin in a patient with HER2.sup.+ breast cancer who progressed after trastuzumab and lapatinib: a case report

  Authors:Claudia Casanova, Alberto Verlicchi, Valentina Mazza, and Claudio DazziFrom:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20152,705 words Clinical report 1490LAuthor(s): Claudia Casanova [*] aff1 , Alberto Verlicchi aff1 , Valentina Mazza aff1 , Claudio Dazzi aff1 KEYWORDS eribulin mesylate; HER2+ breast cancer patient; trastuzumab The HER2 was identified a quarter...

• Response to eribulin in a difficult-to-treat, heavily pretreated breast cancer patient: a case report

  Authors:Luigi Leo, Francesca Caputo, Antonella Di Sarno, Tiziana Garofano, Francesca Andreozzi, Maria Grazia Massaro, et al.From:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20152,137 words Clinical report 1550LAuthor(s): Luigi Leo [*] aff1 , Francesca Caputo aff1 , Antonella Di Sarno aff1 , Tiziana Garofano aff1 , Francesca Andreozzi aff1 , Maria Grazia Massaro aff1 , Vincenzo Montesarchio aff1 KEYWORDS breast cancer;...

• Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient

  Authors:Monica Iorfida and Manuelita MazzaFrom:Future Oncology (Vol. 11, Issue 15s) Peer-Reviewed

  Aug. 20152,628 words Report 1790LAuthor(s): Monica Iorfida [*] aff1 , Manuelita Mazza aff1 KEYWORDS breast cancer; eribulin; response Eribulin mesylate (Halaven® , INN: eribulin mesilate, E7389) is a nontaxane microtubule dynamics inhibitor,...